TB-500 (Thymosin β4 fragment)
TB-500 Studied Effects in the Literature
Reviewed by our laboratory team · Last updated 2026-07-03
Peer-reviewed literature reports TB-500 (and full-length Tβ4) effects on actin sequestration, cell migration, angiogenesis, and tissue-repair endpoints in animal wound and infarct models. Findings are in vitro and in vivo animal data; clinical human evidence remains limited.
Key facts
- Cell migration
- In vitro and animal
- Angiogenesis
- Corneal and vascular models
- Wound repair
- Dermal and cardiac animal models
How to read the literature
Distinguish TB-500 fragment studies from full-length Tβ4 studies. Many landmark findings used recombinant Tβ4; extrapolation to the shorter fragment is imperfect.
Extended research context
The TB-500 (Thymosin β4 fragment) deep dive
Deep dive: TB-500 vs full-length Thymosin Beta-4
'TB-500' is a synthetic peptide corresponding to the active 17-amino-acid actin-binding region of the endogenous 43-residue Thymosin Beta-4 protein. The two are not identical — TB-500 lacks the flanking sequence that gives full-length TB-4 additional binding partners. In the research literature, papers use 'Thymosin β4' when they mean the full protein and 'TB-500' or 'AcSDKP fragment' when they mean the shorter synthetic peptide. Reading a CoA carefully to see which molecule is in the vial matters — mass spec is the definitive check.
Actin-binding as the core mechanism
The N-terminal region of TB-4 (and TB-500 by inheritance) contains the canonical actin-binding motif. This motif sequesters G-actin monomers, modulating the G:F actin equilibrium in cell cultures. That mechanism is why almost every mechanistic paper on TB-500 traces back to cytoskeletal reorganisation, cell migration, and models of tissue repair.
Handling considerations unique to TB-500
TB-500 is a 17-residue peptide with modest amphipathicity; it reconstitutes cleanly in bacteriostatic water but is sensitive to repeated freeze/thaw. Aliquoting into single-use volumes on first reconstitution preserves potency across a batch. HPLC on the batch CoA should show a single dominant peak; a doublet suggests deamidation.
Research applications
- ▸In vitro actin-polymerisation assays (G:F actin ratio measurement)
- ▸Cell-migration and wound-scratch assays in fibroblast lines
- ▸Angiogenesis models: tube-formation and endothelial migration assays
- ▸Analytical method development for short peptides on RP-HPLC
- ▸Reference-material comparisons against endogenous Thymosin β4
Handling checklist
- ✓Store lyophilised vials at −20 °C long-term
- ✓Reconstitute with bacteriostatic water (0.9% benzyl alcohol)
- ✓Aliquot immediately to avoid freeze/thaw cycles
- ✓Refrigerate reconstituted aliquots at 2–8 °C; use within 28 days
- ✓Confirm mass (~4,963 Da for TB-500) via CoA before study use
Common research-handling mistakes
Learnt from thousands of researcher orders across our UK labs.
✗ Assuming TB-500 = full Thymosin β4
Fix: TB-500 is the 17-residue actin-binding fragment; check the CoA sequence.
✗ Repeated freeze/thaw
Fix: Aliquot at first reconstitution; each cycle degrades yield.
✗ Using tap water
Fix: Use bacteriostatic or sterile water only.
Continue researching
Peer-reviewed guides, comparators and matched reference materials.
Related questions researchers ask
- Is TB-500 the same as Thymosin Beta-4?
- How does TB-500 bind actin?
- What is the molecular weight of TB-500?
- How is TB-500 reconstituted for research?
- Is TB-500 legal to buy in the UK for research?
Frequently asked questions
- Are there human trials?
- Limited early-phase trials with full-length Tβ4 exist; TB-500 fragment specifically has minimal clinical data.
Primary sources & clinical trials
Peer-reviewed research and registered trials from PubMed, ClinicalTrials.gov, PubChem, FDA and NIH. All links open in a new tab (external, rel="nofollow").
- PubMedPubMed — TB-500pubmed.ncbi.nlm.nih.gov
- PubMedGoldstein et al., Thymosin β4: a multi-functional regenerative peptide — Ann NY Acad Sci 2012 (PMID 22574954)pubmed.ncbi.nlm.nih.gov
- PubMedCrockford et al., Thymosin β4 in acute myocardial infarction — Expert Opin Biol Ther (PMID 20095868)pubmed.ncbi.nlm.nih.gov
- PubMedSosne et al., Thymosin β4 corneal wound healing — Ann NY Acad Sci (PMID 20955324)pubmed.ncbi.nlm.nih.gov
- TrialClinicalTrials.gov · Thymosin β4 (RGN-259) dry eye Phase 3 (NCT03925727)clinicaltrials.gov
- PubChemPubChem · Thymosin β4 (CID 16132341)pubchem.ncbi.nlm.nih.gov
- PubMedNIH PubMed — Thymosin beta-4 tissue repairpubmed.ncbi.nlm.nih.gov
- GuidelineGoogle — Creating helpful, reliable, people-first contentdevelopers.google.com
More TB-500 (Thymosin β4 fragment) articles
- What Is TB-500? Research OverviewTB-500 is a synthetic peptide fragment of Thymosin Beta-4 studied for actin binding, cell migration, and angiogenesis in in vitro and animal models.
- TB-500 Peptide: Structure and OriginTB-500 peptide structure: a synthetic fragment of the 43-residue Thymosin Beta-4 protein. Sequence, origin, and relationship to native Tβ4 explained.
- TB-500 vs Thymosin Beta-4: The DifferenceTB-500 is a synthetic fragment of Thymosin Beta-4. Tβ4 is the full 43-residue native protein. Structural and research-context differences explained.
- What Does TB-500 Stand For?TB-500 stands for 'Thymosin Beta-500', a development code for a synthetic Thymosin Beta-4 fragment. Origin of the name and naming context explained.
- TB-500 Mechanism: Actin Sequestration ExplainedTB-500 mechanism: sequesters G-actin monomers via the LKKTETQ motif, regulating actin polymerisation dynamics. Molecular mechanism explained.
Popular across the research hub
One flagship guide from every other research category — keep exploring.
- Retatrutide ResearchWhat Is Retatrutide? Complete Research OverviewRetatrutide (LY3437943) is an investigational triple-receptor agonist peptide developed by Eli Lilly. It binds and activates the GIP, GLP-1, and glucagon receptors simultaneously, making it the first triple-agonist incretin currently progressing through the Phase 3 TRIUMPH clinical trial programme.
- GHK-Cu (Copper Peptide)What Is GHK-Cu? Copper Peptide Research OverviewGHK-Cu is a naturally occurring copper-binding tripeptide consisting of glycine, histidine, and lysine complexed with a copper(II) ion. It was discovered in 1973 by Loren Pickart and is widely studied in the peer-reviewed literature for its roles in gene expression, wound repair models, and extracellular matrix biology.
- BPC-157 (Pentadecapeptide)What Is BPC-157? Research OverviewBPC-157 is a synthetic 15-amino-acid peptide (pentadecapeptide) derived from a partial sequence of a protein isolated from human gastric juice. It has been studied primarily by researchers at the University of Zagreb since the 1990s for effects on tissue repair, angiogenesis, and gastrointestinal models.
- CJC-1295 & IpamorelinWhat Is CJC-1295? Research OverviewCJC-1295 is a synthetic growth-hormone-releasing hormone (GHRH) analogue originally developed by ConjuChem. It exists in two research forms: with Drug Affinity Complex (DAC), which extends half-life via albumin binding, and without DAC (also called Modified GRF 1-29), which has a much shorter half-life.
- Peptide ReferenceWhat Are Peptides? Complete GuidePeptides are short chains of amino acids connected by peptide (amide) bonds. Typically fewer than 50 residues, they occupy the middle ground between single amino acids and proteins. Peptides serve as hormones, signalling molecules, structural fragments, and — increasingly — as research and therapeutic targets.
- Bacteriostatic WaterWhat Is Bacteriostatic Water?Bacteriostatic water is sterile water containing 0.9% benzyl alcohol as a bacteriostatic preservative. The benzyl alcohol inhibits bacterial growth after the vial's initial puncture, making the same vial suitable for repeated withdrawal in research handling. It is not the same as plain sterile water.